Eltrombopag (Revolade®)

Assessment Status Assessment process complete
Drug Eltrombopag
Brand Revolade®
Indication For the treatment adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.
Assessment Process
Full submission received from Applicant 05/02/2016
NCPE assessment completed 01/03/2016
NCPE assessment outcome Full Pharmacoeconomic Evaluation Not Recommended